Hello. Sign In
Standards Store

Atlas of Differential Diagnosis in Neoplastic Hematopathology

March 21, 2014

Complete Document



Detail Summary

Active, Most Current

EN
Additional Comments:
ISBN: 978-1-4822-1221-1 * THIRD EDITION
Format
Details
Price (USD)
Print
Backordered
$495.00
Add to Cart

Product Details:

  • Revision: March 21, 2014
  • Published Date: January 2000
  • Status: Active, Most Current
  • Document Language: English
  • Published By: CRC Press (CRC)
  • Page Count: 908
  • ANSI Approved: No
  • DoD Adopted: No

Description / Abstract:

Preface

The field of neoplastic hematology is changing rapidly and the management of patients relies more than ever on morphologic, immunophenotypic, karyotypic, and genetic characteristics. We are witnessing the emergence of truly individualized approaches to treatment; therefore, morphologic and even extensive immunophenotypic analyses of tumors are not suf- cient anymore, as diagnosis, prognosis, and treatment strategies depend heavily on the molecular makeup of tumors. Acute myeloid leukemias (AMLs) are now classied based on specic chromosomal changes and mutational status of an expanding list of genes. The prognosis of patients with AML cannot be established by a single methodology such as metaphase cytogenetics or even evaluation of the mutation of one gene [e.g., concomitant KIT mutations occurring in the context of core-binding factor-positive AML confer a negative prognosis and NPM1+ AML has a good prognosis only if associated with wild-type fms-related tyrosine kinase 3gene (FLT3)]. The list of mature B- and T-cell lymphoproliferations, both nodal and extranodal, continues to expand and includes (among others) "gray zone" lymphomas (double-hit lymphomas), T-cell lymphomas with a follicular T-helper phenotype, and numerous morphologic and immunophenotypic variants of diffuse large B-cell lymphoma. Myeloproliferative neoplasms are classied based on the status of JAK2, BCR– ABL1, KIT, and PDGFRA, with morphologic analysis of the bone marrow still playing a crucial role. Flow cytometric analysis with 6-, 8-, or even 10-color methodologies helps in the diagnosis and subclassication of acute leukemias as well as B- and T-cell lymphomas, but is also expanding its role in patients with myelodysplastic syndrome (MDS) or myeloproliferative neoplasms. The role of ow cytometry in the analysis of blood, effusions, cerebrospinal uid (CSF), and limited samples cannot be overemphasized.

This updated and expanded third edition focuses, as before, on the differential diagnosis, but in addition describes the detailed morphologic, immunophenotypic, and especially genetic characteristics of the majority of hematolymphoid malignancies. To ease the navigation through the text and almost 900 gures, the atlas is divided into 11 sections and47 chapters. Each chapter ends with the most relevant and updated references.

As with the prior editions, this book would not be possible without help of my colleagues and co-workers from Bio- Reference Laboratories (Elmwood Park, New Jersey) and CSI Laboratories (Alpharetta, Georgia). Special thanks for the whole ow cytometry and FISH departments from CSI Laboratories.

I would like to thank Claire Bonnett and the whole editorial crew at CRC Press/Taylor & Francis Group for their invaluable help and support.